Diabetic Macular Edema Market Report 2025 (Global Edition)

Global Diabetic Macular Edema Market Report 2025 Market Size Split by Drug (Anti-VEGF, Corticosteroid Therapies, Other Off-label Drugs), by Form (Intravitreal Injections, Intravitreal Implants), by Di...

Diabetic Macular Edema Market Report Description

We have various report editions of Diabetic Macular Edema Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Impact of Tariff Trumph on Pharmaceuticals Industry

The reintroduction of tariffs under President Trump’s “Liberation Day Tariffs” in April 2025 has created significant disruption in global pharmaceutical trade. These tariffs, ranging from 10% to 46%, specifically target pharmaceutical products, APIs (active pharmaceutical ingredients), medical packaging, and machinery from key manufacturers in China and India. This has led to increased production costs, supply chain delays, and regulatory challenges for U.S.-based pharmaceutical companies.

The tariffs have particularly impacted generic drug manufacturers, who rely heavily on APIs from China and India. Biopharmaceuticals and vaccines are also feeling the pressure, with tariffs on critical materials like bioproduction media and cold-chain packaging raising costs by up to 25%. Similarly, contract manufacturing organizations (CMOs) are grappling with the need to identify new suppliers and adjust production plans to mitigate rising costs.

Foreign governments, including the European Union, have retaliated with tariffs on U.S. pharmaceutical exports, further complicating global trade. Clinical trials are also impacted, as tariffs on drugs and diagnostic kits delay trial timelines.

Market research is increasingly crucial for navigating these challenges. By providing real-time data on API pricing, supplier reliability, and tariff impact, pharmaceutical firms can make informed decisions on sourcing, compliance, and investment strategies. This data-driven approach helps mitigate risks, optimize supply chains, and identify alternative manufacturing hubs to offset tariff-related disruptions.

Overall, market research is essential for pharmaceutical companies to adapt to the new tariff landscape, enabling them to maintain competitive advantage and navigate global trade dynamics effectively.

Diabetic Macular Edema Market Insights Video

Competitive Landscape of the Diabetic macular edema Market

The market for diabetic macular edema (DME) treatments is fiercely competitive, with numerous pharmaceutical companies striving to develop innovative therapies. Pricing strategies, regulatory approvals, and partnerships with healthcare providers are vital factors influencing market dynamics as companies vie for market share in this rapidly evolving landscape.

Top Companies Market Share in Diabetic Macular Edema Industry: (In no particular order of Rank)

• LEO Pharma A/S (Denmark)
• Amneal Pharmaceuticals LLC (US)
• Glenmark Pharmaceuticals Limited (India)
• Dr. Reddy's Laboratories Ltd. (India)
• AstraZeneca (UK)
• Johnson & Johnson Private Limited (US)
• Bausch Health Companies Inc. (Canada)
• Eli Lilly and Company (US)
• AbbVie Inc (US)
• Abbott (US)
• F Hoffmann-La Roche Ltd (Switzerland)
• Mylan N V (US)
• Teva Pharmaceutical Industries Ltd (Israel)
• Sanofi (France)
• Novartis AG (Switzerland)
• Sun Pharmaceutical Industries Ltd (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Allergan (Ireland)
• Merck & Co Inc (US)
• IRIDEX Corporation (US)
• Pfizer Inc.(US)
• GlaxoSmithKline plc (UK)
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of Diabetic Macular Edema Market

Which Region Dominates the Diabetic Macular Edema Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024 and accounted for around 40% of the global revenue. The region boasts advanced healthcare infrastructure, a high prevalence of diabetes, and extensive research and development activities. The region's focus on technological innovation and the presence of market players contribute to the spread of treatment options and improved patient outcomes, positioning North America as a significant hub for DME management.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific stands out as the fastest-growing region in the diabetic macular edema market due to the prevalence of diabetes and increasing awareness about DME-related complications. Countries like China, India, and Japan are major contributors to market expansion, driven by advancements in healthcare infrastructure and increasing adoption of innovative treatment options. Additionally, supportive government initiatives and strategic collaborations further propel market growth in the region.

The current report Scope analyzes Diabetic Macular Edema Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

North America Diabetic Macular Edema Market Analysis

According to Cognitive Market Research, the global diabetic macular edema market size was estimated at USD 3951.2 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 1580.48 million in 2024 and will grow at a compound annual growth rate (CAGR) of -0.2% from 2024 to 2031. In North America, the diabetic macular edema market exhibits a promising landscape characterized by technological advancements in diagnostic tools and treatment options, increasing prevalence of diabetes, rising awareness about eye health, and supportive government initiatives. Additionally, a growing elderly population and lifestyle changes contributing to diabetes incidence further propel market growth. These factors collectively stimulate research and development efforts, leading to innovative therapies and better patient outcomes in the management of DME within the North American region.

• According to Cognitive Market Research, the US had a major share in the diabetic macular edema market with a market size of USD 1247.00 million in 2024 and is projected to grow at a CAGR of -0.4% during the forecast period. The demand is amplified by the nation's rising awareness about DME diagnosis and treatment and advancements in diagnostic technologies.
• The Canadian diabetic macular edema market had a market share of USD 189.66 million in 2024 and is projected to grow at a CAGR of 0.6% during the forecast period. Canada's robust aging population and lifestyle changes to increased usage of diabetic macular edema.
• The Mexico diabetic macular edema  market is projected to witness growth at a CAGR of 0.3% during the forecast period, with a market size of USD 143.82 million in 2024

Europe Diabetic Macular Edema Market Analysis

According to Cognitive Market Research,  the global diabetic macular edema market size was estimated at USD 3951.2 Million, out of which Europe held the market of more than 30% of the global revenue with a market size of USD 1185.36 million in 2024 and will grow at a compound annual growth rate (CAGR) of 0.1% from 2024 to 2031. In Europe, the diabetic macular edema market presents a dynamic landscape characterized by the increasing prevalence of diabetes, rising geriatric population, advancements in diagnostic technologies, and growing awareness about treatment options. Additionally, favorable reimbursement policies and government initiatives aimed at improving healthcare infrastructure further propel market growth. Moreover, collaborations between companies and research institutions for the development of novel therapeutics contribute to the expansion of the DME market in Europe.

• The United Kingdom's diabetic macular edema market had a market share of USD 199.14 million in 2024 and is projected to grow at a CAGR of 0.9% during the forecast period. In the UK, diabetic macular edema sales witness an upswing due to the nation's aging population and rising awareness regarding eye health.
• The French diabetic macular edema market is projected to grow at a CAGR of -0.7% during the forecast period, reaching a market size of USD 109.05 million in 2024.
• According to Cognitive Market Research, the German diabetic macular edema market was valued at USD 234.70 million in 2024 and is projected to grow at a CAGR of 0.3% during the forecast period. In Germany, diabetic macular edema sales surge due to the nation's increasing geriatric population and growing awareness regarding early detection and treatment options.
• The Italian diabetic macular edema market is projected to grow at a CAGR of -0.5% during the forecast period, reaching a market size of USD 101.94 million in 2024.
• The Russian diabetic macular edema market is projected to grow at a CAGR of -0.9% during the forecast period, reaching USD 183.73 million in 2024.
• The Spanish diabetic macular edema market is projected to grow at a CAGR of -0.8% during the forecast period, reaching a market size of USD 97.20 million in 2024.
• The Luxembourg diabetic macular edema market is projected to grow at a CAGR of 2.6% during the forecast period, reaching a market size of USD 20.01 million in 2024.
• The Portugal diabetic macular edema market is projected to grow at a CAGR of -0.1% during the forecast period, reaching a market size of USD 24.89 million in 2024.
• The Greek diabetic macular edema market is projected to grow at a CAGR of 2.8% during the forecast period, reaching a market size of USD 7.74 million in 2024.
• The rest of Europe's diabetic macular edema market is projected to witness growth at a CAGR of -1.2% during the forecast period, with a market size of USD 183.73 million in 2024. 

Asia Pacific Diabetic Macular Edema Market Analysis

According to Cognitive Market Research, the global diabetic macular edema market size was estimated at USD 3951.2 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 908.78 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.6% from 2024 to 2031. In the Asia Pacific region, the diabetic macular edema market exhibits robust growth prospects driven by the increasing prevalence of diabetes, the rising aging population, the adoption of unhealthy lifestyles, and the improvement of healthcare infrastructure, which contribute to market growth. Additionally, advancements in diagnostic technologies and treatment modalities, along with government initiatives to address diabetic complications, further stimulate market expansion. Moreover, growing awareness among patients and healthcare professionals about DME management enhances market prospects, driving demand for effective therapeutic interventions in the region. According to Cognitive Market Research, the China diabetic macular edema market size was valued at USD 408.95 million in 2024 and is projected to grow at a CAGR of 3.1% during the forecast period. Diabetic macular edema sales surged in China due to the nation's government initiatives promoting early detection and management, further fueling the growth. The Japan diabetic macular edema market is projected to witness growth at a CAGR of 2.1% during the forecast period, with a market size of USD 125.41 million in 2024. The Indian diabetic macular edema market had a market share of USD 109.05 million in 2024 and is projected to grow at a CAGR of 5.4% during the forecast period. The demand is augmented by India's improving healthcare infrastructure and rising disposable income. The South Korean diabetic macular edema market is projected to grow at a CAGR of 2.7% during the forecast period, reaching a market size of USD 90.88 million in 2024. The Australian diabetic macular edema market is projected to grow at a CAGR of 3.3% during the forecast period, reaching a market size of USD 47.26 million in 2024. The Southeast Asia diabetic macular edema market is projected to grow at a CAGR of 4.6% during the forecast period, reaching a market size of USD 62.71 million in 2024. The Rest of the Asia Pacific diabetic macular edema market is projected to witness growth at a CAGR of 3.4% during the forecast period, with a market size of USD 64.52 million in 2024. .

South America Diabetic Macular Edema Market Analysis

According to Cognitive Market Research, the global diabetic macular edema market size was estimated at USD 3951.2 Million, out of which Latin America market of more than 5% of the global revenue with a market size of USD 197.56 million in 2024 and will grow at a compound annual growth rate (CAGR) of 1.0% from 2024 to 2031. In Latin America, the diabetic macular edema market showcases promising growth prospects driven by factors such as the increasing prevalence of diabetes, rising awareness about eye health, advancements in diagnostic technologies, and the availability of novel treatment options. Additionally, improving healthcare infrastructure and favorable government initiatives to address diabetic complications contribute to market growth. Furthermore, collaborations between pharmaceutical companies and healthcare organizations for research and development activities are propelling advancements in DME treatment and fostering market expansion in the region.

• According to Cognitive Market Research, the Brazil diabetic macular edema market size was valued at USD 84.56 million in 2024 and is projected to grow at a CAGR of 1.6% during the forecast period. Diabetic macular edema sales flourish in Brazil due to the nation's aging population and improved healthcare infrastructure.
• The Argentina diabetic macular edema market had a market share of USD 33.19 million in 2024 and is projected to grow at a CAGR of 1.9% during the forecast period. Argentina's government initiatives for better healthcare infrastructure and reimbursement policies augment the demand.
• The Colombia diabetic macular edema market is projected to witness growth at a CAGR of 0.8% during the forecast period, with a market size of USD 17.58 million in 2024.
• The Peru diabetic macular edema market is projected to witness growth at a CAGR of 1.2% during the forecast period, with a market size of USD 16.20 million in 2024.
• The Chile diabetic macular edema market is projected to grow at a CAGR of 1.3% during the forecast period, reaching a market size of USD 14.22 million in 2024.
• The Rest of the Latin American diabetic macular edema market is projected to witness growth at a CAGR of 0.1% during the forecast period, with a market size of USD 31.81 million in 2024

Middle East Diabetic Macular Edema Market Analysis

According to Cognitive Market Research, the global diabetic macular edema market size was estimated at USD 3951.2 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 79.02 million in 2024 and will grow at a compound annual growth rate (CAGR) of 1.3% from 2024 to 2031. MEA, the diabetic macular edema market, showcases promising growth prospects driven by factors such as the increasing prevalence of diabetes, rising awareness about diabetic eye diseases, advancements in diagnostic technologies, and the growing adoption of combination therapies. Moreover, initiatives by healthcare organizations to enhance screening programs and improve access to treatment further fuel market growth. Additionally, supportive government policies and investments in healthcare infrastructure contribute to expanding the DME market in the region.

• The GCC Countries' diabetic macular edema market is projected to witness growth at a CAGR of 2.1% during the forecast period, reaching USD 33.82 million in 2024. Diabetic macular edema sales flourish due to advancements in healthcare infrastructure and government initiatives for diabetes management.
• The Egypt diabetic macular edema market is projected to grow at a CAGR of 1.6% during the forecast period, reaching a market size of USD 8.30 million in 2024.
• The South African diabetic macular edema market is projected to grow at a CAGR of 2.3% during the forecast period, reaching USD 12.49 million in 2024. Diabetic macular edema sales flourish in South Africa due to the prevalence of diabetes and rising awareness about DME.
• The Turkish diabetic macular edema market is projected to grow at a CAGR of 0.8% during the forecast period, reaching a market size of USD 6.80 million in 2024.
• The Nigeria diabetic macular edema market is projected to grow at a CAGR of 0.4% during the forecast period, reaching a market size of USD 8.30 million in 2024.
• The Rest of the MEA diabetic macular edema market is projected to witness growth at a CAGR of 0.3% during the forecast period, with a market size of USD 9.32 million in 2024. 

Diabetic Macular Edema Market Analysis

Diabetic macular edema Market Drug Segment Analysis

According to Cognitive Market Research, anti-VEGF stands out as the dominating category. Anti-VEGF drugs, such as aflibercept, ranibizumab, and bevacizumab, target the overproduction of VEGF, which contributes to vascular leakage and edema in the macula. These therapies aim to reduce fluid accumulation and improve vision.

Corticosteroid Therapies emerge as the fastest-growing category in the diabetic macular edema market. Corticosteroids, like dexamethasone implants and fluocinolone acetonide implants, work by suppressing inflammation and reducing vascular permeability. They offer an alternative for patients who may not respond adequately to anti-VEGF treatment or require longer-lasting effects.

• Anti-VEGF 
• Corticosteroid Therapies 
• Other Off-label Drugs

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Diabetic Macular Edema Industry. Request a Free Sample PDF!

Diabetic Macular Edema Market Form Segment Analysis

According to Cognitive Market Research, the dominating category is intravitreal injections. These involve the direct administration of medication into the vitreous cavity of the eye, offering a targeted approach to treating DME. This method typically involves frequent injections to maintain therapeutic levels of medication.

The fastest-growing category in the diabetic macular edema market is intravitreal implants. They are sustained-release devices implanted into the eye to deliver medication gradually over time, reducing the need for frequent injections.

• Intravitreal Injections 
• Intravitreal Implants

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Diabetic Macular Edema Distribution Channel Segment Analysis

According to Cognitive Market Research, the dominating category is hospitals. Hospitals, with their comprehensive healthcare infrastructure and multidisciplinary teams, serve as vital distribution channels for DME treatments. They offer a range of services which include diagnostics, treatment, and post-treatment care.

The fastest-growing category in the diabetic macular edema market is specialty clinics. Specialty Clinics, with their focus on specific medical conditions like DME, provide specialized care and often have advanced diagnostic and treatment capabilities tailored to the needs of DME patients.

• Hospitals
• Specialty Clinics
• Mail Order Pharmacies

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion